SUNRAY 01

Global Pivotal Study in Participants with KRAS G12C-Mutant,
Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treament of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression